Foursan Group has successfully exited its investment in Moroccan generics manufacturer Polymedic, realizing significant returns and demonstrating the company's robust growth and commitment to ESG standards.

Target Information

Foursan Group has successfully exited its investment in Polymedic, a prominent generics manufacturing company based in Morocco. Founded in 2001, Polymedic boasts a diverse portfolio of over 200 registered products spanning 12 therapeutic areas. The company has recently achieved record revenues and profitability, highlighting its robust operational performance.

Over the period of Foursan Group’s investment, Polymedic expanded its workforce by 67%, resulting in a total of 250 employees, with 56% of the workforce being female. This growth underscores Polymedic’s commitment to inclusive development and its adherence to best-in-class environmental, social, and governance (ESG) standards.

Industry Overview in Morocco

The pharmaceutical industry in Morocco has witnessed significant growth over the past decade, driven by increasing healthcare demands and government initiatives aimed at enhancing healthcare access and pharmaceu